Sanders Morris Harris LLC Acquires New Holdings in CVS Health Corporation $CVS

Sanders Morris Harris LLC bought a new stake in shares of CVS Health Corporation (NYSE:CVS) during the third quarter, HoldingsChannel reports. The fund bought 6,674 shares of the pharmacy operator’s stock, valued at approximately $576,000.

Several other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of CVS Health in the second quarter worth $12,747,462,000. State Street Corp lifted its position in shares of CVS Health by 26.3% in the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock valued at $7,751,205,000 after acquiring an additional 15,604,883 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of CVS Health by 148.0% during the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after acquiring an additional 13,836,701 shares during the last quarter. Pzena Investment Management LLC acquired a new stake in shares of CVS Health during the second quarter valued at $1,217,558,000. Finally, Wellington Management Group LLP boosted its stake in shares of CVS Health by 49.8% during the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after acquiring an additional 11,233,381 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of NYSE:CVS opened at $90.42 on Thursday. The company has a market cap of $115.64 billion, a P/E ratio of 23.92, a P/E/G ratio of 0.82 and a beta of 0.60. The business has a fifty day simple moving average of $91.88 and a 200-day simple moving average of $92.87. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The firm had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts forecast that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be issued a dividend of $0.6650 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Thursday, October 22nd. CVS Health’s dividend payout ratio is presently 70.37%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna reported strong 2027 Medicare Advantage ratings. More than 69% of Aetna’s Medicare Advantage members are enrolled in plans rated four stars or higher by CMS for 2027, supporting the business’s quality reputation and potentially helping preserve bonus payments and member retention. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: Analysts see CVS as favorably positioned within Medicare Advantage. A comparison with Alignment Healthcare highlighted CVS’s stronger recent returns, rising earnings estimates and lower valuation, with Aetna’s turnaround cited as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: CVS is expanding pharmacy access. The company opened its first pharmacy-focused location in the Boston area, designed to improve access to medications, immunizations and other pharmacy services in underserved communities. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: MinuteClinic received its seventh consecutive Joint Commission accreditation. The recognition, including evaluation under medical-center standards, reinforces CVS’s healthcare-services credentials; approximately 80% of surveyed locations offer primary care. MinuteClinic earns seventh consecutive Joint Commission accreditation
• Negative Sentiment: CVS agreed to pay $315 million to resolve a Justice Department opioid case. The government alleged that CVS pharmacies improperly filled medically unnecessary or invalid controlled-substance prescriptions from 2013 through 2025 and submitted false claims to federal programs. CVS admitted no wrongdoing and disagreed with the allegations, but the settlement creates a substantial cash cost and includes enhanced monitoring and controlled-substance oversight obligations. CVS Agrees to Pay $315M for Opioid Prescription Allegations

Wall Street Analysts Forecast Growth

CVS has been the subject of several analyst reports. Barclays boosted their target price on shares of CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. Royal Bank Of Canada lifted their price target on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Wall Street Zen raised shares of CVS Health from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Argus upped their price objective on shares of CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Twenty investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $107.80.

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.